News for ACADIA Pharmaceuticals Inc. (0A4W.L)

Bank of America has revised its price target for Acadia Pharmaceuticals (ACAD), reducing it slightly from $19 to $18. Despite this adjustment, the bank maintain

Summary ACADIA Pharmaceuticals Inc (ACAD) announced on April 3, 2025, that its Compensation Committee has granted inducement awards to twenty-two new employees

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 3, 2025, the Compensation Committee of Acadia's Board of Directors (the ”œCommittee”

Acadia Pharmaceuticals (ACAD) granted inducement awards to 22 new employees under its 2024 Inducement Plan. The awards include stock options for 172,637

On March 17, 2025, Baker Bros. Advisors LP executed a significant transaction involving Immunocore Holdings PLC. The firm added 807,338 shares to its holdings,

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the ”œCommittee”

The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fi

On March 5, 2025, Elizabeth Garofalo, Director at ACADIA Pharmaceuticals Inc (ACAD), sold 4,919 shares of the company, according to a SEC Filing. Following this

ACADIA Pharmaceuticals Inc (ACAD) and Saniona have announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending

On February 28, 2025, Baker Bros. Advisors LP executed a significant transaction involving BeOne Medicines Ltd (ONC). The firm reduced its holdings by 470,215 s

Total Revenue (Q4 2024): $259.6 million, up 12% year over year.Total Revenue (Full Year 2024): $957.8 million, up 32% from the prior year.DAYBUE Sales (Q4 2024

Feb 26, 2025 / 09:30PM GMTOperator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals conference call. My name is Shannon, and I will be

Jan 14, 2025 / 05:00PM GMTTessa Romero - JPMorgan Chase & Co - Analyst Welcome, everyone, to the 43rd Annual JPMorgan Healthcare Conference. My name is Tess Rom

Dec 03, 2024 / 03:15PM GMTYigal Nochomovitz - Citigroup Global Markets Inc. - Analyst Okay. Great. All right. Welcome, everyone. I'm Yigal Nochomovitz, one of t

May 16, 2024 / 04:20PM GMTTazeen Ahmad - BofA Securities, Research Division - MD in Equity Research & Research Analyst Joining us again at the Bank of America H

May 14, 2024 / 05:30PM GMTJason Nicholas Butler - JMP Securities LLC, Research Division - MD, Director of Healthcare Research & Equity Research Analyst Excited

ACADIA Pharmaceuticals Inc (ACAD) showcases a robust product portfolio with FDA-approved drugs NUPLAZID® and DAYBUEâ„¢.The company's market capitalization sto

ACADIA Pharmaceuticals Inc (ACAD) has announced its participation in a fireside chat at TD Cowen's 45th Annual Health Care Conference, scheduled for Wednesday,